MAXCYTE, INC.·4

Jun 24, 4:17 PM ET

Ross Thomas M. 4

4 · MAXCYTE, INC. · Filed Jun 24, 2024

Insider Transaction Report

Form 4
Period: 2024-06-20
Ross Thomas M.
EVP, Global Sales
Transactions
  • Sale

    Common Stock

    2024-06-20$4.09/sh33,333$136,46525,000 total
  • Exercise/Conversion

    Common Stock

    2024-06-20$1.64/sh+33,333$54,69958,333 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2024-06-2033,33366,667 total
    Exercise: $1.64Exp: 2030-01-20Common Stock (33,333 underlying)
Footnotes (3)
  • [F1]The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024.
  • [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The option has fully vested.

Documents

1 file
  • 4
    form4-06242024_080648.xmlPrimary